Research use only. Read more

Anti-inflammatory

KPV

A C-terminal tripeptide derivative of α-melanocyte-stimulating hormone investigated for melanocortin-independent anti-inflammatory activity in mucosal and dermal tissue models.

Also known as: α-MSH(11-13)

Quick facts

Molecular weight

401 Da

Half-life

0.5 h

Frequency

daily

Admins / wk

7

Routes

SubQ / Oral

Typical dose

200 mcg–500 mcg

Mechanism & positioning

A C-terminal tripeptide derivative of α-melanocyte-stimulating hormone investigated for melanocortin-independent anti-inflammatory activity in mucosal and dermal tissue models.

Researched for: NF-κB pathway downregulation, mucosal inflammation.

Reconstitution defaults

Default vial

5 mg

BAC water

2 mL

Concentration

2500 mcg/mL

Doses per vial

~25

Other stocked vial sizes: 10 mg.

Calculate with this peptide

References

  • Brzoska T et al., Endocr Rev, 2008.

Related peptides in the Anti-inflammatory class

Frequently asked questions about KPV

What is the typical research dose range for KPV?
KPV is most commonly investigated at 200 mcg–500 mcg per administration, daily. These values reflect documented research-stage protocols and are not medical recommendations.
What is the half-life of KPV?
KPV has an approximate plasma half-life of 0.5 hours. Practical steady state is reached after roughly five half-lives — about 0 days under continuous administration.
How is KPV administered in research protocols?
Published research uses subq or oral administration. Typical reconstitution is 5 mg vial in 2 mL of bacteriostatic water, producing a concentration of 2500 mcg/mL.
What vial sizes are commonly available for KPV?
Common stocked vial sizes are 5 mg, 10 mg. The 5 mg vial is the most-used default in published protocols.